EIRGENIX INCEIRGENIX INCEIRGENIX INC

EIRGENIX INC

No trades
See on Supercharts

6589 fundamentals

Key facts

Market capitalization
Founded
CEO
Website
About

EirGenix, Inc. engages in the research and development of biotechnology drugs. Its products and services include Trastuzumab Biosimilar, Pertuzumab Biosimilar, New Formulation, Antibody-Drug Conjugate, Bevacizumab Biosimilar, CRM197 Carrier Protein, and Biosimilar. The company was founded by Li Cheng Liu on December 21, 2012 and is headquartered in New Taipei, Taiwan.

Valuation

Fundamental metrics to determine fair value of the stock

Summary
No data available
There's currently no market capitalization, revenue or net income data to show.
Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends
6589 has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company